Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.63 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.63 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.63 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.63 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.63 |
| ▸ | DTYMK | P23919 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | PPOX | P50336 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30580504 | 1.00 | AKR1C3 (0.63) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL6567226 | 0.90 | KDM4E (0.62) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL19339944 | 0.89 | DTYMK (0.53) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL12326834 | 0.87 | ALDH1A1 (0.53) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL147187 | 0.87 | AKR1C3 (0.63) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL404510 | 0.85 | MAPT (0.51) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL4946199 | 0.85 | AKR1C3 (0.51) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| Hydrochloric Acid SCHEMBL11773334 | 0.85 | AKR1C3 (0.61) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| Potassium Ion SCHEMBL15876122 | 0.85 | AKR1C3 (0.51) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL268414 | 0.85 | TDP1 (0.62) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 644 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-110629246-B | Vantanib and analogue intermediate electro-reduction preparation method thereof | 湖南大学 | 2021-03-16 | — | — | CN | claimed |
| CN-107778224-B | Preparation method of betrixaban intermediate | 鲁南制药集团股份有限公司 | 2020-06-26 | — | — | CN | claimed |
| CN-110629246-A | Vantanib and analogue intermediate electro-reduction preparation method thereof | 湖南大学 | 2019-12-31 | — | — | CN | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| CN-105348187-A | Betrixaban structural analogue as well as preparation method and application thereof | ANHUI YIXINMING PHARMACEUTICAL TECHNOLOGY CO LTD | 2016-02-24 | — | — | CN | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| JP-2023604-A | — | — | None | — | — | JP | disclosed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-119841822-A | Pyrimido [5,4-c ] quinoline compound, preparation method, pharmaceutical composition and application thereof | 苏州施安鼎泰生物医药技术有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119285675-A | Self-assembled hole transport material, photoelectric device, and preparation method and application thereof | 天合光能股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240027902-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20230359119-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230305393-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230305394-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| EP-3022206-B1 | EPHA4 INHIBITORS AS NEUROPROTECTIVE AGENTS | UNIV HONG KONG SCIENCE & TECH (HK) | 2023-07-12 | — | — | EP | disclosed |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| CN-113620869-B | Preparation method of betrixaban | 江西同和药业股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. | 2023-02-09 | — | — | US | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| WO-2022224223-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2022-10-27 | — | — | WO | disclosed |
| EP-4073242-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | Kumquat Biosciences Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| CN-111499539-B | Aryl cyanide synthesis method using aryl carboxylic acid as raw material | 南昌大学 | 2022-10-11 | — | — | CN | disclosed |
| CN-115103907-A | Compositions and methods for enhancing immune activity | 金橘生物科技公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-113004241-B | 11, 20-dicarbonyl economic oridonin 14-O-benzoic acid esterified derivative and preparation method and application thereof | 郑州大学 | 2022-07-22 | — | — | CN | disclosed |
| US-20220016257-A1 | ANTI-CDH6 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| CN-111620800-B | Method for preparing aryl methyl selenide compound by decarboxylation, selenylation and methylation of aromatic carboxylic acid | 温州医科大学 | 2021-12-07 | — | — | CN | disclosed |
| EP-3293175-B1 | METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INC (US) | 2021-12-01 | — | — | EP | disclosed |
| CN-113631191-A | Combination of antibody-pyrrolobenzodiazepine derivative conjugates with PARP inhibitors | 第一三共株式会社 | 2021-11-09 | — | — | CN | disclosed |
| CN-113631229-A | Antibody-pyrrolobenzodiazepine derivative conjugates | 第一三共株式会社 | 2021-11-09 | — | — | CN | disclosed |
| CN-113620869-A | Preparation method of betrixaban | 江西同和药业股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-113631190-A | anti-HER 2 antibody-pyrrolobenzodiazepine derivative conjugates | 第一三共株式会社 | 2021-11-09 | — | — | CN | disclosed |
| WO-2021216440-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| CN-109467509-B | Preparation method of substituted nitrobenzene compounds | 联化科技股份有限公司 | 2021-09-24 | — | — | CN | disclosed |
| EP-3882349-A1 | (ANTI-CDH6 ANTIBODY)-(PYRROLOBENZODIAZEPINE DERIVATIVE) CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2021-09-22 | — | — | EP | disclosed |
| CN-113166764-A | anti-CDH 6 antibody-pyrrolobenzodiazepine derivative conjugates | 第一三共株式会社 | 2021-07-23 | — | — | CN | disclosed |
| CN-113004241-A | 11, 20-dicarbonyl economic oridonin 14-O-benzoic acid esterified derivative and preparation method and application thereof | 郑州大学 | 2021-06-22 | — | — | CN | disclosed |
| WO-2021119554-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| CN-107382897-B | Intermediate of betrixaban and preparation method and application thereof | 浙江宏元药业股份有限公司 | 2021-05-04 | — | — | CN | disclosed |
| US-20210107859-A1 | A PROCESS FOR THE SYNTHESIS OF CARBON LABELED ORGANIC COMPOUNDS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2021-04-15 | — | — | US | disclosed |
| US-20210107859-A1 | A PROCESS FOR THE SYNTHESIS OF CARBON LABELED ORGANIC COMPOUNDS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2021-04-15 | — | — | US | disclosed |
| CN-110629246-B | Vantanib and analogue intermediate electro-reduction preparation method thereof | 湖南大学 | 2021-03-16 | — | — | CN | disclosed |
| CN-110629246-B | Vantanib and analogue intermediate electro-reduction preparation method thereof | 湖南大学 | 2021-03-16 | — | — | CN | disclosed |
| EP-3774696-A1 | A PROCESS FOR THE SYNTHESIS OF CARBON LABELED ORGANIC COMPOUNDS | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2021-02-17 | — | — | EP | disclosed |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| CN-111620800-A | Method for preparing aryl methyl selenide compound by decarboxylation, selenylation and methylation of aromatic carboxylic acid | 温州医科大学 | 2020-09-04 | — | — | CN | disclosed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-111499539-A | Aryl cyanide synthesis method using aryl carboxylic acid as raw material | 南昌大学 | 2020-08-07 | — | — | CN | disclosed |
| CN-107778224-B | Preparation method of betrixaban intermediate | 鲁南制药集团股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-107778224-B | Preparation method of betrixaban intermediate | 鲁南制药集团股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| EP-3660010-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| CN-107778223-B | Preparation method of betrixaban maleate | 鲁南制药集团股份有限公司 | 2020-05-15 | — | — | CN | disclosed |
| CN-107325002-B | Method for synthesizing aryl halide by taking aryl carboxylic acid as raw material | 南昌大学 | 2020-03-27 | — | — | CN | disclosed |
| US-10570123-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20200038385-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2020-02-06 | — | — | US | disclosed |
| CN-110629246-A | Vantanib and analogue intermediate electro-reduction preparation method thereof | 湖南大学 | 2019-12-31 | — | — | CN | disclosed |
| CN-110629246-A | Vantanib and analogue intermediate electro-reduction preparation method thereof | 湖南大学 | 2019-12-31 | — | — | CN | disclosed |
| EP-3150590-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2019-10-16 | — | — | EP | disclosed |
| WO-2019193068-A1 | A PROCESS FOR THE SYNTHESIS OF CARBON LABELED ORGANIC COMPOUNDS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-10-10 | — | — | WO | disclosed |
| EP-3549927-A1 | A PROCESS FOR THE SYNTHESIS OF CARBON LABELED ORGANIC COMPOUNDS | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2019-10-09 | — | — | EP | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| US-10406144-B2 | SIP modulating agents | BIOGEN MA INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-2542529-B1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | LLC PHARMADIALL (RU) | 2019-09-04 | — | — | EP | disclosed |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. | 2019-06-13 | — | — | US | disclosed |
| EP-3484878-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | Bristol-Myers Squibb Company (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-3180318-B1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | HYDRA BIOSCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20190046510-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20180369215-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2018-12-27 | — | — | US | disclosed |
| EP-3050871-B1 | NOVEL BIS-AMIDE DERIVATIVE AND USE THEREOF | UNIV INDUSTRY COOPERATION GROUP KYUNG HEE UNIV (KR) | 2018-11-07 | — | — | EP | disclosed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | disclosed |
| US-10064843-B2 | Bis-amide derivative and use thereof | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2018-09-04 | — | — | US | disclosed |
| US-10039769-B2 | Substituted triazolobenzodiazepines | CONCERT PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10034869-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10034869-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2018-07-31 | — | — | US | disclosed |
| EP-3056207-B1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMA CO LTD (JP) | 2018-06-20 | — | — | EP | disclosed |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2018-03-15 | — | — | US | disclosed |
| EP-3293175-A1 | METHODS FOR PURIFICATION OF SERINE PROTEASES | Portola Pharmaceuticals, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20180028511-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA | 2018-02-01 | — | — | US | disclosed |
| US-20180028511-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA | 2018-02-01 | — | — | US | disclosed |
| US-9879020-B2 | GABAA agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma | UWM RESEARCH FOUNDATION, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879020-B2 | GABAA agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma | UWM RESEARCH FOUNDATION, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
| US-9856219-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170326119-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170326119-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9808449-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9808449-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9808449-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2938596-B1 | METHODS FOR PURIFICATION OF SERINE PROTEASES | PORTOLA PHARM INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2938596-B1 | METHODS FOR PURIFICATION OF SERINE PROTEASES | PORTOLA PHARM INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170253603-A2 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| US-9745272-B2 | Quinazoline-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745272-B2 | Quinazoline-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745272-B2 | Quinazoline-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9708265-B2 | Urethanes, ureas, amidines and related inhibitors of factor Xa | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2017-07-18 | — | — | US | disclosed |
| EP-3180318-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | Hydra Biosciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2017091757-A1 | ISOTOPICALLY ENRICHED BETRIXABAN | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-9644195-B2 | Compounds and methods for purification of serine proteases | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9644195-B2 | Compounds and methods for purification of serine proteases | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9644195-B2 | Compounds and methods for purification of serine proteases | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9630947-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-9629830-B2 | EphA4 inhibitors as neuroprotective agents | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2017-04-25 | — | — | US | disclosed |
| US-9630947-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| EP-3150590-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3150590-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9555023-B2 | Pharmaceutical salts and polymorphs of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9555023-B2 | Pharmaceutical salts and polymorphs of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| WO-2016205739-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | MEKONNEN BELEW (US) | 2016-12-22 | — | — | WO | disclosed |
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2016-11-24 | — | — | US | disclosed |
| EP-2513058-B1 | METHODS OF SYNTHESIZING FACTOR XA INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-2513058-B1 | METHODS OF SYNTHESIZING FACTOR XA INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9475822-B2 | Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-20160297751-A1 | NOVEL BIS-AMIDE DERIVATIVE AND USE THEREOF | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2016-10-13 | — | — | US | disclosed |
| US-20160279117-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-09-29 | — | — | US | disclosed |
| US-20160263093-A1 | S1P modulating agents | BIOGEN MA INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160263093-A1 | S1P modulating agents | BIOGEN MA INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160263093-A1 | S1P modulating agents | BIOGEN MA INC. | 2016-09-15 | — | — | US | disclosed |
| US-9440961-B2 | Rho-kinase inhibitors and method of preparation | SURFACE LOGIX, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9433618-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2672823-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-3056207-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-08-17 | — | — | EP | disclosed |
| EP-2521549-B1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMA CO LTD (JP) | 2016-08-17 | — | — | EP | disclosed |
| EP-3056207-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-20160220556-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2016-08-04 | — | — | US | disclosed |
| EP-3050871-A1 | NOVEL BIS-AMIDE DERIVATIVE AND USE THEREOF | University-Industry Cooperation Group of Kyung Hee University (KR) | 2016-08-03 | — | — | EP | disclosed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | disclosed |
| US-9364481-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160152618-A1 | EphA4 INHIBITORS AS NEUROPROTECTIVE AGENTS | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2016-06-02 | — | — | US | disclosed |
| EP-2315763-B1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-3022206-A1 | EphA4 INHIBITORS AS NEUROPROTECTIVE AGENTS | The Hong Kong University of Science and Technology (CN) | 2016-05-25 | — | — | EP | disclosed |
| US-9340527-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340527-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340527-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340574-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-9315462-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160101089-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2016-04-14 | — | — | US | disclosed |
| US-20160101089-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2016-04-14 | — | — | US | disclosed |
| US-20160067254-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-03-10 | — | — | US | disclosed |
| EP-1976849-B1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME (US) | 2016-03-09 | — | — | EP | disclosed |
| CN-105348187-A | Betrixaban structural analogue as well as preparation method and application thereof | ANHUI YIXINMING PHARMACEUTICAL TECHNOLOGY CO LTD | 2016-02-24 | — | — | CN | disclosed |
| US-20160046601-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-02-18 | — | — | US | disclosed |
| WO-2016023826-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023826-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| EP-2977050-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | Nivalis Therapeutics, Inc. (US) | 2016-01-27 | — | — | EP | disclosed |
| US-9221758-B2 | Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221758-B2 | Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221758-B2 | Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221836-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-29 | — | — | US | disclosed |
| US-9221810-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | disclosed |
| US-9212149-B2 | Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150344464-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | KADMON CORPORATION, LLC | 2015-12-03 | — | — | US | disclosed |
| US-9200268-B2 | Compounds and methods for purification of serine proteases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200268-B2 | Compounds and methods for purification of serine proteases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150337285-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY (IE) | 2015-11-26 | — | — | US | disclosed |
| US-20150337285-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY (IE) | 2015-11-26 | — | — | US | disclosed |
| US-20150337285-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY (IE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336897-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2015-11-26 | — | — | US | disclosed |
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2938596-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | Portola Pharmaceuticals, Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| EP-2624695-B1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | NIVALIS THERAPEUTICS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| US-9139528-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150239931-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2015-08-27 | — | — | US | disclosed |
| US-20150232473-A1 | NOVEL GABAA AGONISTS AND METHODS OF USING TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-20 | — | — | US | disclosed |
| US-20150232473-A1 | NOVEL GABAA AGONISTS AND METHODS OF USING TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-20 | — | — | US | disclosed |
| US-20150232473-A1 | NOVEL GABAA AGONISTS AND METHODS OF USING TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-20 | — | — | US | disclosed |
| EP-2897963-A1 | NOVEL GABAA AGONISTS AND METHODS OF USING TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA | UWM Research Foundation, Inc. (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2404906-B1 | Methods of synthesizing pharmaceutical salts of a factor XA inhibitor | MILLENNIUM PHARM INC (US) | 2015-07-15 | — | — | EP | disclosed |
| EP-2404906-B1 | Methods of synthesizing pharmaceutical salts of a factor XA inhibitor | MILLENNIUM PHARM INC (US) | 2015-07-15 | — | — | EP | disclosed |
| EP-1700850-B1 | Phenylalanine derivative | AJINOMOTO KK (JP) | 2015-07-15 | — | — | EP | disclosed |
| US-20150191486-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-07-09 | — | — | US | disclosed |
| EP-1865958-B1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20150183774-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2015-07-02 | — | — | US | disclosed |
| WO-2015095783-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-9061019-B2 | Pharmaceutical salts and polymorphs of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061019-B2 | Pharmaceutical salts and polymorphs of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9045437-B2 | 2-aryl-4-quinazolinones and their pharmaceutical compositions | CHINA MEDICAL UNIVERSITY (TW) | 2015-06-02 | — | — | US | disclosed |
| US-9045436-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| US-9012646-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9006239-B2 | 2-aryl-4-quinazolinones and their pharmaceutical compositions | CHINA MEDICAL UNIVERSITY (TW) | 2015-04-14 | — | — | US | disclosed |
| US-8987463-B2 | Methods of synthesizing factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987463-B2 | Methods of synthesizing factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987463-B2 | Methods of synthesizing factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150080429-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2015-03-19 | — | — | US | disclosed |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2015-02-26 | — | — | US | disclosed |
| US-8946219-B2 | Combination therapy with a compound acting as a platelet ADP receptor inhibitor | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946219-B2 | Combination therapy with a compound acting as a platelet ADP receptor inhibitor | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2015007222-A1 | EphA4 INHIBITORS AS NEUROPROTECTIVE AGENTS | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2015-01-22 | — | — | WO | disclosed |
| US-8921562-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8916576-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140371209-A1 | S1P Modulating Agents | BIOGEN MA INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371209-A1 | S1P Modulating Agents | BIOGEN MA INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371209-A1 | S1P Modulating Agents | BIOGEN MA INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140346397-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY (IE) | 2014-11-27 | — | — | US | disclosed |
| US-20140346397-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY (IE) | 2014-11-27 | — | — | US | disclosed |
| US-20140346397-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY (IE) | 2014-11-27 | — | — | US | disclosed |
| CN-1917881-B | Novel phenylalanine derivatives | AJINOMOTO KK | 2014-11-26 | — | — | CN | disclosed |
| EP-2803667-A1 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2014-11-19 | — | — | EP | disclosed |
| US-20140329821-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | NIVALIS THERAPEUTICS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140288028-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288028-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-8785643-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2014106128-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014106128-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | WO | disclosed |
| US-20140186923-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140186923-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8765723-B2 | Analogues of cilostazol | CONCERT PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765723-B2 | Analogues of cilostazol | CONCERT PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2014055768-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-04-10 | — | — | WO | disclosed |
| WO-2014047413-A1 | NOVEL GABAA AGONISTS AND METHODS OF USING TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA | UWM RESEARCH FOUNDATION, INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014047413-A1 | NOVEL GABAA AGONISTS AND METHODS OF USING TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA | UWM RESEARCH FOUNDATION, INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| EP-2146705-B1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARM INC (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2146705-B1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARM INC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8664380-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-04 | — | — | US | disclosed |
| US-20140046071-A1 | Methods of Synthesizing Pharmaceutical Salts of a Factor Xa Inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140046071-A1 | Methods of Synthesizing Pharmaceutical Salts of a Factor Xa Inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140046071-A1 | Methods of Synthesizing Pharmaceutical Salts of a Factor Xa Inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140018363-A1 | 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS | CHINA MEDICAL UNIVERSITY (TW) | 2014-01-16 | — | — | US | disclosed |
| EP-2672823-A1 | S1P MODULATING AGENTS | Biogen Idec MA Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20130315897-A1 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2013177349-A2 | QUINAZOLINEDIONES AS TANKYRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-11-28 | — | — | WO | disclosed |
| EP-2651223-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8557852-B2 | Methods of using crystalline forms of a salt of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557852-B2 | Methods of using crystalline forms of a salt of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557852-B2 | Methods of using crystalline forms of a salt of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261123-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | NIVALIS THERAPEUTICS, INC. | 2013-10-03 | — | — | US | disclosed |
| EP-2635559-A2 | NEUROTRYPSIN INHIBITORS | Neurotune AG (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-8524907-B2 | Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524907-B2 | Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524907-B2 | Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130211094-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130211094-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130211094-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2624695-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2615087-A2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20130178499-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8476286-B2 | for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476286-B2 | for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476286-B2 | for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8466282-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-18 | — | — | US | disclosed |
| CN-101704799-B | Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof | UNIV COLUMBIA | 2013-06-05 | — | — | CN | disclosed |
| US-8455440-B2 | Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455440-B2 | Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130131021-A1 | ANALOGUES OF CILOSTAZOL | CONCERT PHARMACEUTICALS INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131021-A1 | ANALOGUES OF CILOSTAZOL | CONCERT PHARMACEUTICALS INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131047-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2127654-B1 | Benzothiazepine derivatives as ryanodine receptor (RYR2) inhibitors and their use in the treatment of cardiac diseases | UNIV COLUMBIA (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2591783-A1 | Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2591783-A1 | Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2586439-A1 | Combination therapy with a compound acting as a platelet ADP receptor inhibitor | Portola Pharmaceuticals, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2586439-A1 | Combination therapy with a compound acting as a platelet ADP receptor inhibitor | Portola Pharmaceuticals, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20130102602-A1 | 2-Aryl-4-Quinazolinones And Their Pharmaceutical Compositions | CHINA MEDICAL UNIVERSITY (TW) | 2013-04-25 | — | — | US | disclosed |
| US-8426588-B2 | Phenylalanine derivatives | AJINOMOTO CO, INC. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-8404724-B2 | Administering compound such as N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride for inhibiting coagulation | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404724-B2 | Administering compound such as N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride for inhibiting coagulation | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404724-B2 | Administering compound such as N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride for inhibiting coagulation | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20130064806-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
| US-20130064806-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
| US-8394964-B2 | Methods of synthesizing factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394964-B2 | Methods of synthesizing factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394964-B2 | Methods of synthesizing factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2013033269-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033270-A2 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033270-A2 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033269-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| EP-2101760-B1 | UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR | MILLENNIUM PHARM INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2101760-B1 | UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR | MILLENNIUM PHARM INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8357693-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| EP-1740551-B9 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2542529-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | Tovbin, Dmitry Gennadievich (RU) | 2013-01-09 | — | — | EP | disclosed |
| US-8349817-B2 | Analogues of cilostazol | CONCERT PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349817-B2 | Analogues of cilostazol | CONCERT PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20130005778-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2013-01-03 | — | — | US | disclosed |
| EP-2521549-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-8309561-B2 | N-(2,6-dichlorobenzoyl)-4-[1-methyl-7-(pyrrolidine-1-ylmethyl)-2,4-quinazoline-dione-3-yl]-L-phenylalanine trifluoroacetate; 4 integrin antagonist; antiinflammatory, anticarcinogenic agent, antiallergent; asthma, psoriasis, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation | AJINOMOTO CO., INC. (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2513058-A1 | METHODS OF SYNTHESIZING FACTOR XA INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120264733-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2012-10-18 | — | — | US | disclosed |
| EP-1963294-B1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-20120253041-A1 | NEW PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2012-10-04 | — | — | US | disclosed |
| EP-1740551-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-2163248-B1 | Benzothiazepine derivatives as ryanodine receptor (RYR2) inhibitors and their use in the treatment of cardiac diseases | UNIV COLUMBIA (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2012109108-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202793-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2012-08-09 | — | — | US | disclosed |
| US-8227492-B2 | Sulfoxamine derivatives as factor Xa inhibitors | CADILA HEALTHCARE LIMITED (IN) | 2012-07-24 | — | — | US | disclosed |
| US-8222405-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2012-07-17 | — | — | US | disclosed |
| WO-2012083165-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2012048181-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012040499-A2 | METABOLIC INHIBITORS | SURFACE LOGIX, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| EP-2431358-A1 | Method of preparing a factor XA inhibitor | Millennium Pharmaceuticals, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2431358-A1 | Method of preparing a factor XA inhibitor | Millennium Pharmaceuticals, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1948608-B1 | PHARMACEUTICAL SALTS AND POLYMORPHS OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO)IMINOMETHYL]BENZOYL]AMINO]-5-METHOXY-BENZAMIDE , A FACTOR XA INHIBITOR | MILLENNIUM PHARM INC (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-1948608-B1 | PHARMACEUTICAL SALTS AND POLYMORPHS OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO)IMINOMETHYL]BENZOYL]AMINO]-5-METHOXY-BENZAMIDE , A FACTOR XA INHIBITOR | MILLENNIUM PHARM INC (US) | 2012-03-14 | — | — | EP | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046230-A1 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor | MILLENNIUM PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120046230-A1 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor | MILLENNIUM PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| EP-2077995-B1 | METHODS OF SYNTHESIZING PHARMACEUTICAL SALTS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARM INC (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2077995-B1 | METHODS OF SYNTHESIZING PHARMACEUTICAL SALTS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARM INC (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2406236-A1 | RHO KINASE INHIBITORS | Surface Logix, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-2404906-A1 | Methods of synthesizing pharmaceutical salts of a factor XA inhibitor | Millennium Pharmaceuticals, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2404906-A1 | Methods of synthesizing pharmaceutical salts of a factor XA inhibitor | Millennium Pharmaceuticals, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319627-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-12-29 | — | — | US | disclosed |
| US-20110319627-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-12-29 | — | — | US | disclosed |
| US-20110319627-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-12-29 | — | — | US | disclosed |
| CN-1980677-B | Novel antiarrhythmic and heart failure drugs targeting the leakage of ryanodine receptor (RYR2) and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-12-21 | — | — | CN | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-8022058-B2 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-09-20 | — | — | US | disclosed |
| WO-2011112731-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011108963-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | TOVBIN DMITRY GENNADIEVICH (RU) | 2011-09-09 | — | — | WO | disclosed |
| US-7998972-B2 | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2011-08-16 | — | — | US | disclosed |
| US-20110178057-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | disclosed |
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | disclosed |
| WO-2011084519-A1 | METHODS OF SYNTHESIZING FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084519-A1 | METHODS OF SYNTHESIZING FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011082337-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORP. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| EP-2324029-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| EP-2297114-A2 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20110065717-A1 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2011-03-17 | — | — | US | disclosed |
| US-20110065918-A1 | NEW PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110033459-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110033459-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| EP-1288205-B1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO KK (JP) | 2011-02-02 | — | — | EP | disclosed |
| US-7879840-B2 | Ryanodine receptors (RyRs) modulators comprising 1,4-benzothiazepine derivatives, that regulate calcium channel functioning in cells, used for the treatment of cardiovascular disorders and muscular disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879840-B2 | Ryanodine receptors (RyRs) modulators comprising 1,4-benzothiazepine derivatives, that regulate calcium channel functioning in cells, used for the treatment of cardiovascular disorders and muscular disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879890-B2 | hydantoin derivatives that can inhibit matrix metalloproteinases and tumor necrosis factor alpha-converting enzyme, to prevent the release of tumor necrosis factor; treatment of septic shock, reperfusion injuries, meningitis, psoriasis, arthritis, inflammatory bowel disease and ankylosing spondylitis | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-7872125-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2011-01-18 | — | — | US | disclosed |
| EP-1956054-B1 | Phase change ink | XEROX CORP (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| CN-101857617-A | Quinazoline sugar derivative and preparation method and application thereof | OCEAN UNIV CHINA | 2010-10-13 | — | — | CN | disclosed |
| WO-2010114563-A1 | METABOLITES OF K201 (JTV-519) (4- [3-{1- (4- BENZYL) PIPERIDINYL} PROPIONYL] -7 -METHOXY 2, 3, 4, 5-TETRAHYDRO-1,4-BENZOTHIAZEPINE MONOHYDROCHLORIDE | SEQUEL PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114562-A1 | IMPROVED METHODS OF ADMINISTRATION OF K201 (JTV-519) (4-[3-{1-(4-BENZYL) PIPERIDINYL}PROPIONYL]-7-METHOXY 2, 3, 4, 5-TETRAHYDRO-1, 4-BENZOTHIAZEPINE MONOHYDROCHLORIDE) | SEQUEL PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114562-A1 | IMPROVED METHODS OF ADMINISTRATION OF K201 (JTV-519) (4-[3-{1-(4-BENZYL) PIPERIDINYL}PROPIONYL]-7-METHOXY 2, 3, 4, 5-TETRAHYDRO-1, 4-BENZOTHIAZEPINE MONOHYDROCHLORIDE) | SEQUEL PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249079-A1 | ANALOGUES OF CILOSTAZOL | CONCERT PHARMACEUTICALS INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249079-A1 | ANALOGUES OF CILOSTAZOL | CONCERT PHARMACEUTICALS INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2010104851-A1 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-1778676-B1 | HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORP (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100197929-A1 | METHODS OF SYNTHESIZING PHARMACEUTICAL SALTS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100197929-A1 | METHODS OF SYNTHESIZING PHARMACEUTICAL SALTS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100197929-A1 | METHODS OF SYNTHESIZING PHARMACEUTICAL SALTS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100152440-A1 | NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2) | MARKS ANDREW ROBERT | 2010-06-17 | — | — | US | disclosed |
| US-20100152440-A1 | NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2) | MARKS ANDREW ROBERT | 2010-06-17 | — | — | US | disclosed |
| US-20100152440-A1 | NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2) | MARKS ANDREW ROBERT | 2010-06-17 | — | — | US | disclosed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | disclosed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100137587-A1 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-06-03 | — | — | US | disclosed |
| EP-2191832-A1 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| EP-2191832-A1 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| EP-2188257-A2 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | Cadila Healthcare Limited (IN) | 2010-05-26 | — | — | EP | disclosed |
| EP-2186813-A1 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SmithKline Beecham (Cork) Limited (IE) | 2010-05-19 | — | — | EP | disclosed |
| US-7718644-B2 | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718644-B2 | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718644-B2 | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-05-18 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| CN-101704799-A | Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof | UNIV COLUMBIA | 2010-05-12 | — | — | CN | disclosed |
| US-7704990-B2 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-04-27 | — | — | US | disclosed |
| US-7704990-B2 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1477482-B1 | NOVEL PHENYLALANINE DERIVATIVE | AJINOMOTO KK (JP) | 2010-04-14 | — | — | EP | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| US-7687527-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7683085-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| WO-2010030785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| EP-2163248-A1 | Benzothiazepine derivatives as ryanodine receptor (RYR2) inhibitors and their use in the treatment of cardiac diseases | The Trustees of Columbia University in the City of New York (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20100063113-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100063113-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100063113-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2010-03-11 | — | — | US | disclosed |
| EP-2155195-A2 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | Millennium Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-02-18 | — | — | US | disclosed |
| EP-2146705-A2 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | Portola Pharmaceuticals, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2009154300-A2 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-23 | — | — | WO | disclosed |
| EP-2127654-A1 | Benzothiazepine derivatives as ryanodine receptor (RYR2) inhibitors and their use in the treatment of cardiac diseases | The Trustees of Columbia University in the City of New York (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-26 | — | — | US | disclosed |
| EP-1401451-B1 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7605165-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-7598276-B2 | Better thermal and hydrolytic stability than the free-base compounds; N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride | MILLENIUM PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598276-B2 | Better thermal and hydrolytic stability than the free-base compounds; N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride | MILLENIUM PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598276-B2 | Better thermal and hydrolytic stability than the free-base compounds; N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride | MILLENIUM PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2101760-A2 | UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR | Millennium Pharmaceuticals, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-1809284-A4 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2077995-A1 | METHODS OF SYNTHESIZING PHARMACEUTICAL SALTS OF A FACTOR XA INHIBITOR | Millennium Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090170875-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-07-02 | — | — | US | disclosed |
| CN-100502845-C | Compound for treating and preventing arrhythmia caused by exercise and preparation method thereof | UNIV COLUMBIA (US) | 2009-06-24 | — | — | CN | disclosed |
| US-7544678-B2 | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544678-B2 | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544678-B2 | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090137586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| WO-2009053999-A2 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2009-04-30 | — | — | WO | disclosed |
| US-20090111803-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-04-30 | — | — | US | disclosed |
| EP-1734969-A4 | NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) AND USES THEREOF | UNIV COLUMBIA (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7504424-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-7488745-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7482370-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1684735-A4 | COMPOUNDS AND METHODS FOR TREATING AND PREVENTING EXERCISE-INDUCED CARDIAC ARRHYTHMIAS | UNIV COLUMBIA (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| WO-2008137787-A2 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137787-A2 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080279845-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080279845-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080279845-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| EP-1216228-B1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | MILLENNIUM PHARM INC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| WO-2008127682-A2 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127682-A2 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080254036-A1 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080254036-A1 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080254036-A1 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-7427630-B2 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMACO PUERTO RICO INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427630-B2 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMACO PUERTO RICO INC. (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1963294-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| EP-1509521-B1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| EP-1958993-A1 | Phase change inks containing colorant compounds | Xerox Corporation (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1956054-A2 | Colorant compounds | Xerox Corporation (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080187664-A1 | Phase change inks containing colorant compounds | XEROX CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20080184910-A1 | Mixture of basic dye and wax | XEROX CORPORATION | 2008-08-07 | — | — | US | disclosed |
| EP-1953148-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1948608-A2 | PHARMACEUTICAL SALTS AND POLYMORPHS OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO)IMINOMETHYL]BENZOYL]AMINO]-5-METHOXY-BENZAMIDE , A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-7393652-B2 | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393652-B2 | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-07-01 | — | — | US | disclosed |
| US-20080153876-A1 | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153876-A1 | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153876-A1 | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008073670-A2 | UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073670-A2 | UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008057972-A1 | METHODS OF SYNTHESIZING PHARMACEUTICAL SALTS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057972-A1 | METHODS OF SYNTHESIZING PHARMACEUTICAL SALTS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20080108634-A1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2008-05-08 | — | — | US | disclosed |
| EP-1917245-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | Abbott GmbH & Co. KG (DE) | 2008-05-07 | — | — | EP | disclosed |
| CN-101146785-A | Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RYR2) | UNIV COLUMBIA (US) | 2008-03-19 | — | — | CN | disclosed |
| US-7345049-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1865958-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | Surface Logix, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1861385-A1 | NOVEL ANTI-ARRYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) | The Trustees of Columbia University in the City of New York (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1861707-A2 | NOVEL ANTI-ARRYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) | The Trustees of Columbia University in the City of New York (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-09-20 | — | — | US | disclosed |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-09-20 | — | — | US | disclosed |
| US-20070185078-A1 | Substituted triazole derivatives as oxytocin antagonists | PFIZER, INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007084415-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-26 | — | — | US | disclosed |
| EP-1809284-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2007067613-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| CN-1980677-A | Novel antiarrhythmic and heart failure drugs targeting the leakage of ryanodine receptor (RYR2) and uses thereof | UNIV COLUMBIA (US) | 2007-06-13 | — | — | CN | disclosed |
| WO-2007056517-A2 | PHARMACEUTICAL SALTS AND POLYMORPHS OF N- (5-CHL0R0-2-PYRIDINYL) -2- [ [4- [ (DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO] -5-METH OXY-BENZAMIDE, A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056517-A2 | PHARMACEUTICAL SALTS AND POLYMORPHS OF N- (5-CHL0R0-2-PYRIDINYL) -2- [ [4- [ (DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO] -5-METH OXY-BENZAMIDE, A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112039-A1 | Better thermal and hydrolytic stability than the free-base compounds; N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride | MILLENNIUM PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112039-A1 | Better thermal and hydrolytic stability than the free-base compounds; N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride | MILLENNIUM PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112039-A1 | Better thermal and hydrolytic stability than the free-base compounds; N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride | MILLENNIUM PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| EP-1765811-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070066640-A1 | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-03-22 | — | — | US | disclosed |
| EP-1758910-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Pfizer Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| WO-2007024717-A2 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYR RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049572-A1 | Novel agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049572-A1 | Novel agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2007022946-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2007-03-01 | — | — | WO | disclosed |
| CN-1917881-A | Novel phenylalanine derivatives | AJINOMOTO KK (JP) | 2007-02-21 | — | — | CN | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1740551-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1734969-A2 | NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2006-12-27 | — | — | EP | disclosed |
| CN-1886122-A | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | UNIV COLUMBIA (US) | 2006-12-27 | — | — | CN | disclosed |
| US-7153963-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| EP-1724268-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-7129245-B2 | Anticoagulants which act selectively on factor Xa; fast acting; oral; do not interfere with lysis of blood clots | ELI LILLY AND COMPANY (US) | 2006-10-31 | — | — | US | disclosed |
| WO-2006105081-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060223836-A1 | New phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2006-10-05 | — | — | US | disclosed |
| WO-2006101497-A2 | NOVEL ANTI-ARRYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006101496-A1 | NOVEL ANTI-ARRYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-28 | — | — | US | disclosed |
| EP-1700850-A1 | NOVEL PHENYLALANINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-09-13 | — | — | EP | disclosed |
| EP-1684735-A2 | COMPOUNDS AND METHODS FOR TREATING AND PREVENTING EXERCISE-INDUCED CARDIAC ARRHYTHMIAS | The Trustees of Columbia University in the City of New York (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1185869-B1 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | GRAFFINITY PHARMACEUTICALS AG (DE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006052555-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ | 2006-04-06 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-7002022-B2 | N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF | NOVARTIS AG (CH) | 2006-02-21 | — | — | US | disclosed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | disclosed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-20060020039-A1 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | US | disclosed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| CN-1724532-A | Colorant compound | XEROX CORP (US) | 2006-01-25 | — | — | CN | disclosed |
| EP-1614676-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-01-11 | — | — | EP | disclosed |
| WO-2006002383-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| EP-1611133-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC. CSC, The United States Corporation Company (PR) | 2006-01-04 | — | — | EP | disclosed |
| US-20050282862-A1 | Aromatic amides | BEIGHT DOUGLAS W | 2005-12-22 | — | — | US | disclosed |
| WO-2005121152-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| US-20050245562-A1 | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-11-03 | — | — | US | disclosed |
| WO-2005094457-A2 | NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1583531-A1 | HETEROARYL- SUBSTITUTED PYRROLO' 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB Pharmco Puerto Rico Inc (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050222141-A1 | Novel phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2005-10-06 | — | — | US | disclosed |
| US-20050215540-A1 | Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2005-09-29 | — | — | US | disclosed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | disclosed |
| US-20050186640-A1 | Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RYR2) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-25 | — | — | US | disclosed |
| US-20050187386-A1 | Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2005-08-25 | — | — | US | disclosed |
| US-20050153357-A1 | Bioactive sensors | EICHLER JUTTA (DE) | 2005-07-14 | — | — | US | disclosed |
| US-20050101779-A1 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2005-05-12 | — | — | US | disclosed |
| WO-2005037195-A2 | COMPOUNDS AND METHODS FOR TREATING AND PREVENTING EXERCISE-INDUCED CARDIAC ARRHYTHMIAS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OFNEW YORK (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | disclosed |
| US-6878720-B2 | VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| EP-1509521-A2 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-02 | — | — | EP | disclosed |
| US-6844367-B1 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-6825191-B2 | ANTICOAGULANT | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20040229781-A1 | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2004-11-18 | — | — | US | disclosed |
| US-20040229781-A1 | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2004-11-18 | — | — | US | disclosed |
| US-20040229781-A1 | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2004-11-18 | — | — | US | disclosed |
| EP-1477482-A1 | NOVEL PHENYLALANINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004094420-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
| US-20040180912-A1 | Quinazoline derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| EP-1140903-B1 | AROMATIC AMIDES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2004062665-A1 | HETEROARYL- SUBSTITUTED PYRROLO` 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-07-29 | — | — | WO | disclosed |
| US-6759414-B2 | ANTICOAGULANTS WHICH ACT SELECTIVELY ON FACTOR XA; FAST ACTING; ORAL; DO NOT INTERFERE WITH LYSIS OF BLOOD CLOTS | ELI LILLY AND COMPANY | 2004-07-06 | — | — | US | disclosed |
| US-20040077690-A1 | Quaternary amidino based inhibitors of factor xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-0765871-B1 | Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors | FIBROGEN INC (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1401451-A2 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-20040029874-A1 | Aromatic amides | BEIGHT DOUGLAS WADE (US) | 2004-02-12 | — | — | US | disclosed |
| US-6677452-B1 | PREPARED BY REACTING AMINE WITH PYRIDINE SUBSTITUTED WITH HALOGEN AT POSITION 6 AND WITH CARBOXY OR SULFONYL GROUP AT ANOTHER POSITION TO FORM AMIDE OR SULFONAMIDE, DISPLACING HALOGEN WITH DESIRED DIAMINE | LION BIOSCIENCE AG (DE) | 2004-01-13 | — | — | US | disclosed |
| US-20030220268-A1 | New phenylalanine derivatives | AJINOMOTO CO. INC (JP) | 2003-11-27 | — | — | US | disclosed |
| WO-2003097641-A2 | 1H-IMIDAZO[4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-11-27 | — | — | WO | disclosed |
| US-6635657-B1 | Pyridine derivatives; anticoagulants | ELI LILLY AND COMPANY | 2003-10-21 | — | — | US | disclosed |
| US-20030186969-A1 | Benzodiazepine derivatives | AJINOMOTO CO. INC (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1329450-A1 | BENZODIAZEPINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-07-23 | — | — | EP | disclosed |
| EP-1322637-A2 | QUATERNARY AMIDINO BASED INHIBITORS OF FACTOR XA | Millennium Pharmaceuticals, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6548525-B2 | Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| EP-1288205-A1 | NOVEL PHENYLALANINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2003-03-05 | — | — | EP | disclosed |
| WO-2002102782-A2 | QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE | NOVARTIS AG (CH) | 2002-12-27 | — | — | WO | disclosed |
| US-6479499-B1 | INHIBITORS OF TUBULIN POLYMERIZATION | NATIONAL SCIENCE COUNCIL (TW) | 2002-11-12 | — | — | US | disclosed |
| US-20020127577-A1 | Bioactive sensors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-09-12 | — | — | US | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| EP-1216228-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2002026731-A2 | QUATERNARY AMIDINO BASED INHIBITORS OF FACTOR XA | MILLENIUM PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| EP-1185869-A2 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | Graffinity Pharmaceutical Design GmbH (DE) | 2002-03-13 | — | — | EP | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
| US-20020016326-A1 | Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| EP-1140903-A1 | AROMATIC AMIDES | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1129075-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2001-09-05 | — | — | EP | disclosed |
| US-6271237-B1 | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY | 2001-08-07 | — | — | US | disclosed |
| WO-1999032454-A9 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | DU PONT PHARM CO (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001019788-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000073796-A2 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | GRAFFINITY PHARMACEUTICAL DESIGN GMBH (DE) | 2000-12-07 | — | — | WO | disclosed |
| EP-1042299-A1 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000039118-A1 | AROMATIC AMIDES | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000027820-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999032454-A1 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5883282-A | UREA CHEMICAL INTERMEDIATES; RICE | AMERICAN CYANAMID COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| WO-1998045272-A1 | TOPOISOMERASE INHIBITORS | LATROBE UNIVERSITY (AU) | 1998-10-15 | — | — | WO | disclosed |
| US-5763605-A | 3-(3-aryloxyphenyl)-1-(substituted methyl)-S-triazine-2,4,6-oxo or thiotrione herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1998-06-09 | — | — | US | disclosed |
| US-5726305-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-03-10 | — | — | US | disclosed |
| US-5719164-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-17 | — | — | US | disclosed |
| US-5670641-A | 3-(3-aryloxyphenyl)-1-(substituted methyl)-S-triazine-2,4,6-oxo or thiotrione herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| US-5654256-A | PREEMERGENCE, POSTEMERGENCE HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0765871-A1 | Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-02 | — | — | EP | disclosed |
| US-5604180-A | RICE CROPS | AMERICAN CYANAMID COMPANY | 1997-02-18 | — | — | US | disclosed |
| EP-0745595-A1 | 3-(3-Aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents | American Cyanamid Company (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5519133-A | CYCLIZATION, ALKYLATION | AMERICAN CYANAMID CO. (US) | 1996-05-21 | — | — | US | disclosed |
| EP-0625978-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-30 | — | — | EP | disclosed |
| WO-1993016073-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-19 | — | — | WO | disclosed |
| JP-H0223604-A | ELECTROLYTIC SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR | NICHICON CORP | 1990-01-25 | — | — | JP | disclosed |
| US-3954396-A | MONOAZO | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) | 1976-05-04 | — | — | US | disclosed |
| US-3954396-A | MONOAZO | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264733-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | AKR1C3 181/4885AKR1C2 232/4885AKR1B10 452/4885 |
| US-20130315897-A1 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor | SERPINC1, F2, TFPI | AKR1C3 2816/4885AKR1C2 3575/4885AKR1B10 3693/4885 |
| US-20080108634-A1 | NOVEL PHENYLALANINE DERIVATIVES | ITGB4, ITGA4, ITGAV | AKR1C3 3658/4885AKR1C2 4054/4885AKR1B10 3318/4885 |
| US-20050222141-A1 | Novel phenylalanine derivatives | ITGB4, ITGA4, ITGAV | AKR1C3 3658/4885AKR1C2 4054/4885AKR1B10 3318/4885 |
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | CRH, CRHR1, CRHR2 | AKR1C3 925/4885AKR1C2 1245/4885AKR1B10 2092/4885 |
| US-20130131021-A1 | ANALOGUES OF CILOSTAZOL | PDE3A, PDE3B, PDE5A | AKR1C3 628/4885AKR1C2 514/4885AKR1B10 894/4885 |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | RYR1, RYR2, ATP2A1 | AKR1C3 256/4885AKR1C2 251/4885AKR1B10 525/4885 |
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | AKR1C3 128/4885AKR1C2 92/4885AKR1B10 142/4885 |
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | AKR1C3 803/4885AKR1C2 1153/4885AKR1B10 1138/4885 |
| US-20160279117-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | AKR1C3 18/4885AKR1C2 19/4885AKR1B10 49/4885 |
| US-20200038385-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | AKR1C3 1405/4885AKR1C2 1800/4885AKR1B10 1756/4885 |
| US-10039769-B2 | Substituted triazolobenzodiazepines | BET1, BRD4, BRPF3 | AKR1C3 2489/4885AKR1C2 2426/4885AKR1B10 2917/4885 |
| US-20130178499-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | AKR1C3 128/4885AKR1C2 92/4885AKR1B10 142/4885 |
| US-20050245562-A1 | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | ABL1, PRKCA, PRKCQ | AKR1C3 3488/4885AKR1C2 3026/4885AKR1B10 3297/4885 |
| US-20090111803-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | AKR1C3 1065/4885AKR1C2 1136/4885AKR1B10 1051/4885 |
| US-20040077690-A1 | Quaternary amidino based inhibitors of factor xa | F12, TFPI, F11 | AKR1C3 1744/4885AKR1C2 1955/4885AKR1B10 2384/4885 |
| US-20070049572-A1 | Novel agents for preventing and treating disorders involving modulation of the RyR receptors | RYR2, RYR1, ATP2A1 | AKR1C3 706/4885AKR1C2 598/4885AKR1B10 795/4885 |
| US-20170326119-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | F12, F11, TFPI | AKR1C3 705/4885AKR1C2 755/4885AKR1B10 1052/4885 |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | AKR1C3 1010/4885AKR1C2 1043/4885AKR1B10 1180/4885 |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | AKR1C3 4367/4885AKR1C2 3993/4885AKR1B10 3779/4885 |
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | MMP13, MMP14, MMP25 | AKR1C3 853/4885AKR1C2 1230/4885AKR1B10 1852/4885 |
| US-20130102602-A1 | 2-Aryl-4-Quinazolinones And Their Pharmaceutical Compositions | AQP4, KRAS, RB1 | AKR1C3 29/4885AKR1C2 143/4885AKR1B10 606/4885 |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | AKR1C3 2643/4885AKR1C2 1872/4885AKR1B10 1891/4885 |
| US-20020016326-A1 | Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors | F12, F11, F2 | AKR1C3 525/4885AKR1C2 1402/4885AKR1B10 1854/4885 |
| US-20060020039-A1 | Benzamides and related inhibitors of factor Xa | TFPI, F12, F11 | AKR1C3 3570/4885AKR1C2 3468/4885AKR1B10 2861/4885 |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | AKR1C3 4503/4885AKR1C2 4492/4885AKR1B10 4406/4885 |
| US-20140371209-A1 | S1P Modulating Agents | S1PR2, S1PR1, S1PR3 | AKR1C3 2602/4885AKR1C2 2829/4885AKR1B10 3048/4885 |
| US-20110178057-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | AKR1C3 531/4885AKR1C2 586/4885AKR1B10 948/4885 |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | AKR1C3 472/4885AKR1C2 1545/4885AKR1B10 2273/4885 |
| US-20100249079-A1 | ANALOGUES OF CILOSTAZOL | PDE3A, PDE3B, PDE5A | AKR1C3 628/4885AKR1C2 514/4885AKR1B10 894/4885 |
| US-20190046510-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | F12, F11, TFPI | AKR1C3 705/4885AKR1C2 755/4885AKR1B10 1052/4885 |
| US-20140046071-A1 | Methods of Synthesizing Pharmaceutical Salts of a Factor Xa Inhibitor | F12, F11, TFPI | AKR1C3 839/4885AKR1C2 1005/4885AKR1B10 1133/4885 |
| US-20040029874-A1 | Aromatic amides | F11, F12, F5 | AKR1C3 1343/4885AKR1C2 891/4885AKR1B10 1257/4885 |
| US-20150336897-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | AKR1C3 128/4885AKR1C2 92/4885AKR1B10 142/4885 |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | AKR1C3 744/4885AKR1C2 697/4885AKR1B10 1402/4885 |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | AKR1C3 744/4885AKR1C2 697/4885AKR1B10 1402/4885 |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | AKR1C3 1206/4885AKR1C2 1248/4885AKR1B10 858/4885 |
| US-20150337285-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | PRSS1, HPN, PRSS8 | AKR1C3 2888/4885AKR1C2 3197/4885AKR1B10 3656/4885 |
| US-20090170875-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | AKR1C3 1010/4885AKR1C2 1043/4885AKR1B10 1180/4885 |
| US-20070066640-A1 | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | CRHR1, CRHR2, CRH | AKR1C3 458/4885AKR1C2 714/4885AKR1B10 797/4885 |
| US-20060223836-A1 | New phenylalanine derivatives | ITGB4, ITGA4, ITGAV | AKR1C3 3474/4885AKR1C2 3912/4885AKR1B10 3145/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | AKR1C3 4618/4885AKR1C2 4720/4885AKR1B10 4669/4885 |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | TRPC5, HTR5A, TRPV5 | AKR1C3 666/4885AKR1C2 1034/4885AKR1B10 2033/4885 |
| US-20130064806-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | F12, F11, TFPI | AKR1C3 705/4885AKR1C2 755/4885AKR1B10 1052/4885 |
| US-20120046230-A1 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor | SERPINC1, F2, TFPI | AKR1C3 2816/4885AKR1C2 3575/4885AKR1B10 3693/4885 |
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | AKR1C3 163/4885AKR1C2 295/4885AKR1B10 776/4885 |
| US-10034869-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | AKR1C3 832/4885AKR1C2 979/4885AKR1B10 1149/4885 |
| US-20180028511-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | AKR1C3 1405/4885AKR1C2 1800/4885AKR1B10 1756/4885 |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | AKR1C3 4330/4885AKR1C2 4225/4885AKR1B10 3774/4885 |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | AKR1C3 513/4885AKR1C2 1040/4885AKR1B10 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.